Form D · Biotechnology
ThelioPulse, Inc.
Los Angeles, CA · CIK 0001544558
Offering snapshot reported Feb 27, 2014 · SEC filing
- Reported sold
- $0 Offering amount: $220K
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 17, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 27, 2014 | Initial | $0 | No comparison | 0 | SEC filing |
| Mar 15, 2012 | Initial | $5,125,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-212634
Options to purchase common stock issued pursuant to equity incentive plan and underlying common stock issuable upon exercise thereof.
Source: Form D, filed Feb 27, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gary Hutchinson | Executive |
| Jonathan G. Lasch | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Denney Research Building 1042 Downey Way, Drb 101
Los Angeles, CA, 90089-1112
Los Angeles, CA, 90089-1112